JDH2501 JDH JAN5
- 28.37
- 0.000.00%
JDH JAN5 News
**** had a phone call with the elected president of the USA, Trump.
**** congratulated Trump on being re-elected as President of the USA, pointing out that both sides highly value each other's interactions and hope that the China-US relationship has a good start in the new term of the USA President, wishing to promote greater progress in the China-US relationship from this new starting point.
Last year, the medical insurance Fund in the mainland was balanced with a slight surplus.
The press conference held by the National Medical Insurance Bureau stated that in 2024, the Medical Insurance Fund will balance its revenue and expenditure, with a slight surplus, ensuring the fund's safety and sustainability. According to preliminary aggregated data from the Medical Insurance Fund, in 2024, the total income of the national basic medical insurance fund will be 3.48 trillion yuan (RMB), an annual increase of 4.4%. The total expenditure of the national basic medical insurance fund will be 2.97 trillion yuan, an annual increase of 5.5%. The current surplus of the national medical insurance pooling fund is 470 billion yuan, with a cumulative balance of 3.87 trillion yuan. At the same time, the number of outpatient settlements in the national basic medical insurance has reached 6.7 billion visits, an annual increase of 19%. The maternity insurance fund is pending.
The National Bureau of Statistics: In 2024, the total domestic product will be 134,908.4 billion yuan, with a growth of 5.0% compared to the previous year.
Looking at it by quarters, the gross domestic product grew by 5.3% year-on-year in the first quarter, 4.7% in the second quarter, 4.6% in the third quarter, and 5.4% in the fourth quarter. In terms of quarter-on-quarter, the gross domestic product grew by 1.6% in the fourth quarter.
Express News | ICBC International has given HANSOH PHARMA an initial buy rating, with a Target Price of 22.10 HKD. It has assigned a neutral initial rating to JD HEALTH, with a Target Price of 30.40 HKD. INNOVENT BIO has been given an initial buy rating, with a Target P
Macquarie has listed investment ratings and Target Prices for Chinese internet stocks (table).
Macquarie released a report listing investment ratings and target prices for Chinese internet stocks: Stock│Investment Rating│Target Price Alibaba-W (09988.HK)│Outperform│HKD 135.5 Baidu (09888.HK)│Neutral│HKD 83 JD (09618.HK)│Outperform│HKD 217 NetEase (09999.HK)│Outperform│HKD 198 ALI HEALTH (00241.HK)│Underperform│HKD 3.4 JD HEALTH (06618.HK)│Underperform│HKD 23.3 JD Logistics (02618.HK)│Outperform
Four bullish factors come together! Hong Kong stocks and A-shares surge collectively, with the Hang Seng TECH Index rising over 2%, and foreign capital attitude is showing a shift.
Against the backdrop of a significant decline in the Japanese stock market, the A-shares market has shown impressive performance in the Asia-Pacific region. In the early trading today, the number of stocks that rose exceeded 5,000, and all three major Indices went up. The A50 even surged sharply, and the Hong Kong stock market was also boosted.
Hong Kong market update | The decline of the Hong Kong stock market narrowed in the afternoon, with most Biotechnology stocks trending down, WUXI XDC dropping over 12%; Semiconductors stocks rose against the trend, Semiconductor Manufacturing Internationa
Network Technology stocks fell, Baidu Group-SW dropped 2.32%, XIAOMI-W fell 2.24%; Apple Supplier stocks declined, Q TECH fell 5.35%, BYD Electronic dropped 4.73%; Photovoltaic Power stocks mostly declined, FLAT GLASS fell 7.01%, XINYI SOLAR dropped 2.55%;
[Brokerage Focus] Tianfeng maintains a "Buy" rating for JD HEALTH (06618), Bullish on its continuous strengthening as a self-operated Pharmaceutical E-commerce.
Tianfeng released a Research Report indicating that the signing ceremony for the strategic cooperation between JD HEALTH (06618) and China Resources Sanjiu Medical & Pharmaceutical was held at JD's Global Headquarters in Peking. In the coming year, both parties will deepen cooperation in the fields of pharmaceutical retail across all channels, pharmaceutical digital marketing, and corporate social responsibility, establishing a new benchmark for comprehensive cooperation in pharmaceutical retail, jointly leading the high-quality development of the Industry, and maximizing the social value of enterprises. The firm pointed out that leveraging JD HEALTH's advantage as the "first station for the full launch of new specialty drugs on the entire network," JD HEALTH will assist China Resources Sanjiu in making more new drugs and good medicines accessible to the public.
JD HEALTH (06618.HK) has released a comprehensive medical model "AI Medical" and "JD Medical Expert."
JD HEALTH (06618.HK) released the full series of products "AI JD Medical" based on its online global scenarios and the industry's first large model product for full-scene application in Hospitals called "JD Excellent Medical" at the "2025 JD HEALTH Annual Doctor Ceremony and Digital Medical Conference".
Express News | JD HEALTH has officially launched the Medical large model product system "AI Jingyi".
Hong Kong market quick view | All three major indexes fell by about 1%, Tencent Related stocks all dropped, Weimob plunged over 40%; Golden Industrial Concept stocks rose against the trend, LINGBAO GOLD soared by 20%; Bruker's first day of listing surged
Network Technology stocks have generally fallen, with MEITUAN-W down 2.98% and SenseTime-W down 2.29%; Golden Industrial Concept stocks have all risen, with LINGBAO GOLD up 20.11% and CHINAGOLDINTL up 4.76%; Semiconductor stocks have risen, with HG SEMI up 12.96% and Innoscience up 5.74%;
JD HEALTH (06618.HK) plans to expand its offline medical beauty Business.
According to sources cited by domestic media, JD HEALTH (06618.HK) is actively preparing to expand its offline Medical Beauty Business, which is expected to be led by Yang Wengan, who recently joined the Consumer Medical Business Department at JD HEALTH. Reports indicate that Yang Wengan founded the medical beauty consultation platform "Meidai Fu" in 2018, and in August 2020, Meidai Fu reached a strategic cooperation in internet medical beauty with JD HEALTH and United Lige.
Hong Kong stock afternoon review | The three major indexes all fell, Semiconductors and Golden Industrial Concept rose against the trend, Semiconductor Manufacturing International Corporation increased by over 5%, LINGBAO GOLD surged by over 10%.
Network Technology stocks declined, with MEITUAN-W falling 1.80% and NTES-S rising 1.59%; Golden Industrial Concept stocks rose, LINGBAO GOLD increasing by 10.63% and Zijin Mining Group rising by 3.27%; many Dining stocks dropped, with Helen's falling by 5.66% and Naixue's Tea dropping by 4.07%;
UBS Group: Looking ahead at the structural opportunities in the Medical Care Industry in China this year amidst uncertainty, the top picks are INNOVENT BIO (01801.HK), JD HEALTH (06618.HK), WUXI APPTEC (02359.HK), and Eyebright Medical Technology (Beijing
UBS Group published a Research Report stating that last year the Medical Care industry in China faced challenges, impacted by factors such as domestic medical insurance cost control, weak Consumer market conditions, and geopolitical tensions. However, it is expected that by 2025 the Sector risks will trend upward, with Industry valuations and Instituional Holdings levels at historical lows. Coupled with a macro environment that could be more favorable for industry development, investors are expected to find structural opportunities amidst uncertainty. The report indicated that the momentum for biopharmaceutical development continues, with a Bullish outlook on recent CRO profitability, and believes that the fundamentals of various biotech companies are sound. Furthermore, with government support policies for pharmaceutical innovation, it is believed that there will be rapid growth in product sales.
UBS Group slightly lowered the Target Price for JD HEALTH (06618.HK) to 35.2 yuan, expected last quarter's performance to roughly meet market expectations.
UBS Group issued a report, expecting JD HEALTH (06618.HK) last year's performance to be generally in line with expectations and even likely to exceed market expectations. In terms of revenue, the bank expects that consumer behavior in the fourth quarter of last year may be relatively pessimistic year-on-year, and part of the non-pharmaceutical traffic may have been shifted to government-subsidized products. Additionally, due to weakened demand related to influenza, certain Pharmaceutical products and Medical devices may have faced high base challenges in the fourth quarter of last year. However, the bank anticipates JD HEALTH will achieve revenue growth faster than the Industry last year, mainly benefiting from strong growth in prescription drugs.
Hong Kong Market Quick Review | The three major indices of Hong Kong stocks fluctuated and closed lower; the Cryptos Concept and Nonprofit Pharmaceutical Companies rose against the trend, with BOYAA rising over 12% and Heptagon Pharmaceuticals increasing
Network Technology stocks declined, with MEITUAN-W dropping 1.95% and KUAISHOU-W falling 1.23%; most Dining stocks fell, with HAILUNSI down 4.66% and SUPER HI down 4.15%; Property Services and Management stocks weakened, with GREENTOWN SER down 3.90% and SUNAC SERVICES down 2.53%.
Hong Kong stock Concept tracking | The positive rate of influenza viruses nationwide continues to rise, resulting in an increase in sales of Against Influenza antiviral drugs (including concept stocks).
The national influenza virus positivity rate continues to rise, with over 99% of cases being Type A influenza.
Large Network Technology stocks generally rose. Xiaomi Group (01810) increased by 6.18%. Institutions suggest that AI is expected to empower domestic Internet Plus-Related giants to open up new growth opportunities.
Gold & Wealth News | Network Technology stocks generally rose, with Xiaomi Group (01810) up 6.18%, Meituan (03690) up 3.25%, Alibaba (09988) up 3.01%, JD Group (09618) and JD HEALTH (06618) rising over 2%. BOCOM INTL released a market outlook report, indicating that the Global economy is entering a phase of cyclical transition. It is expected that by 2025, the stock market will have both support and face disturbances, thus suggesting a balanced allocation. In the Internet Plus-Related industry, demand recovery is evident, and there is a Bullish outlook on quality platforms with attractive valuations. The effects of new policies promoting online and offline Consumer spending may manifest the quickest, it is projected that the bank will...
Hong Kong market quick overview | Three major indexes closed lower, the Hang Seng Index fell below 0.02 million points; chip stocks and financial stocks declined, Semiconductor Manufacturing International Corporation fell nearly 9%; Golden Industrial Conc
Network Technology stocks fell, SenseTime-W dropped by 5.37%, JD-SW fell by 2.57%; Securities and Brokerage stocks weakened, Guolian declined by 8.89%, China Merchants fell by 7.25%; many Digital Health stocks went down, JD HEALTH dropped by 6.05%, Dingdang Health fell by 5.00%.
JD HEALTH (06618.HK) granted 0.6432 million shares as reward.
On January 1, Glonghui announced that JD HEALTH (06618.HK) issued a notice stating that on January 1, 2025, the company awarded 0.64323 million new shares as reward shares to the grantees according to the share incentive plan after the initial public offering, accounting for approximately 0.02% of the total issued shares on the grant date.